Menopause Evaluation and Management

Diagnostic Evaluation

• Transvaginal ultrasound is used to evaluate ovarian morphology, assess endometrial thickness, and rule out ovarian masses or tumors, as recommended by the National Comprehensive Cancer Network 1
• The National Comprehensive Cancer Network suggests that increased risk of hormone-sensitive cancers is associated with prolonged estrogen exposure, and counseling is necessary regarding continued fertility potential, need for contraception, and this increased risk 1
• Evaluating endometrial thickness via ultrasound and considering endometrial biopsy if abnormal bleeding is present, endometrial thickness is greater than 4mm in a non-bleeding patient, or there is a history of unopposed estrogen exposure is recommended by the National Comprehensive Cancer Network 1

Hormone Level Monitoring and Management

• The National Comprehensive Cancer Network recommends considering causes of discordant hormone levels, including estrogen-producing ovarian tumors, adrenal pathology, pituitary disorders, and exogenous hormone exposure 2
• If menopausal symptoms are present despite normal FSH, the National Comprehensive Cancer Network suggests considering non-hormonal options first and discussing hormone therapy options if appropriate 2
• Hormone level assessment is crucial for evaluating reproductive health, with a complete hormonal panel including FSH and LH levels, estradiol levels, thyroid function tests, and prolactin levels, as recommended by the American Academy of Neurology and the American College of Obstetricians and Gynecologists 3, 4
• Technical issues with assays can lead to heterogeneity in results; newer automated platform assays are more reliable, as reported by the Endocrine Society 5
• Age-specific reference ranges are vital as AMH levels naturally decline with age, according to the Endocrine Society 5
• Normal follicular phase hormone levels for premenopausal women include estradiol levels between 70-530 pmol/L (or approximately 19-144 pg/mL), as stated by the Society for Endocrinology and the Endocrine Society 5, 6
• The following table summarizes the normal follicular phase estradiol levels in premenopausal women:

FSH Level Interpretation

• FSH is not a reliable marker of menopausal status in women with prior chemotherapy or pelvic radiation exposure, as stated by the National Comprehensive Cancer Network 2
• FSH >35 IU/L indicates ovarian failure, according to the American College of Obstetricians and Gynecologists, in women with primary ovarian insufficiency 7
• Avoid premature diagnosis of primary ovarian insufficiency, as low FSH with regular periods is not consistent with POI, which typically presents with elevated FSH, as recommended by the American College of Obstetricians and Gynecologists 4, 7

Polycystic Ovary Syndrome (PCOS) Evaluation and Management

• PCOS is the most common cause of anovulation, affecting 4-6% of the general population and 10-25% of women with temporal lobe epilepsy, and is characterized by hyperandrogenic chronic anovulation, as noted by the American Academy of Neurology 3
• Transvaginal ultrasound is used to assess ovarian morphology and rule out polycystic ovaries, which is a key diagnostic criterion for PCOS, as recommended by the American Academy of Neurology 3
• For PCOS-related anovulation, consider ovulation induction therapy after addressing other metabolic issues, as recommended by the American College of Obstetricians and Gynecologists 3

Lifestyle Modifications and Supplementations

• Reduce psychological stress, normalize exercise patterns, and ensure adequate nutrition, as recommended by the European Society of Human Reproduction and Embryology 6
• Consider calcium and vitamin D supplementation, and bone mineral density testing if low estrogen is prolonged, to help manage bone health concerns, as recommended by the North American Menopause Society 4, 6

Hormone Therapy

• Consider low-dose hormone therapy with 17β-estradiol and cyclical progestin if symptoms of estrogen deficiency develop, to help manage persistent low estrogen in patients with regular periods, as suggested by the American Society for Reproductive Medicine 3, 8
• The following table summarizes the effects of low estrogen levels on multiple body systems:

Follow-up and Monitoring

• Regular follow-up, including repeat hormonal assessment in 3-6 months, is recommended to track changes in patients with low FSH and low estrogen, and annual monitoring may be sufficient if regular periods continue with stable hormonal patterns, as recommended by the American College of Obstetricians and Gynecologists 4
• An AMH level <0.7 ng/ml is associated with diminished ovarian reserve (DOR), and <0.015 represents an extreme case, according to the American Society for Reproductive Medicine and the European Society of Human Reproduction and Embryology 11